Antibody persistence up to 5 y after vaccination with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in adolescents

References

• Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med 2001; 344:1378-88; PMID:11333996; http://dx.doi.org/10.1056/NEJM200105033441807
   PubMed Web of Science ®Google Scholar
• Cohn AC, MacNeil JR, Harrison LH, Hatcher C, Theodore J, Schmidt M, Pondo T, Arnold KE, Baumbach J, Bennett N, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998–2007: implications for prevention of meningococcal disease. Clin Infect Dis 2010; 50:184-91; PMID:20001736; http://dx.doi.org/10.1086/649209
   PubMed Web of Science ®Google Scholar
• Trotter CL, Chandra M, Cano R, Larrauri A, Ramsay ME, Brehony C, Jolley KA, Maiden MC, Heuberger S, Frosch M. A surveillance network for meningococcal disease in Europe. FEMS Microbiol Rev 2007; 31:27-36; http://dx.doi.org/10.1111/j.1574-6976.2006.00060.x
   PubMed Web of Science ®Google Scholar
• Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009; 27 Suppl 2:B51-63; PMID:19477562; http://dx.doi.org/10.1016/j.vaccine.2009.04.063
   PubMed Web of Science ®Google Scholar
• Nair D, Dawar R, Deb M, Capoor MR, Singal S, Upadhayay DJ, Aggarwal P, Das B, Samantaray JC. Outbreak of meningococcal disease in and around New Delhi, India, 2005–2006: a report from a tertiary care hospital. Epidemiol Infect 2009; 137:570-6; http://dx.doi.org/10.1017/S0950268808001398
   PubMed Web of Science ®Google Scholar
• World Health Organization. Meningococcal disease in the Philippines - update 2. Emergencies preparedness, response programme [Internet]; 2005 Jan 28 [cited 2016 Aug 29]. Available from: http://www.who.int/csr/don/2005_01_28a/en/
   Google Scholar
• Soriano-Gabarro M, Wolter J, Ng T. Historical and emerging meningococcal disease in Asia. Abstract presented at: 5th World Congress of the World Society for Pediatric Infectious Diseases; 2007 Nov 15-18; Bangkok, Thailand
   Google Scholar
• Chiou CS, Liao JC, Liao TL, Li CC, Chou CY, Chang HL, Yao SM, Lee YS. Molecular epidemiology and emergence of worldwide epidemic clones of Neisseria meningitidis in Taiwan. BMC Infect Dis 2006; 6:25; PMID:16412228; http://dx.doi.org/10.1186/1471-2334-6-25
   PubMed Web of Science ®Google Scholar
• Wilder-Smith A, Goh KT, Barkham T, Paton NI. Hajj-associated outbreak strain of Neisseria meningitidis serogroup W135: estimates of the attack rate in a defined population and the risk of invasive disease developing in carriers. Clin Infect Dis 2003; 36:679-83; PMID:12627350; http://dx.doi.org/10.1086/367858
   PubMed Web of Science ®Google Scholar
• Committee on Infectious Diseases. Meningococcal conjugate vaccines policy update: booster dose recommendations. Pediatrics 2011; 128:1213-8; http://dx.doi.org/10.1542/peds.2011-2380
   PubMed Web of Science ®Google Scholar
• Gill CJ, Baxter R, Anemona A, Ciavarro G, Dull P. Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents. Human Vaccines 2010; 6:881-7; http://dx.doi.org/10.4161/hv.6.11.12849
   PubMed Web of Science ®Google Scholar
• Vu DM, Welsch JA, Zuno-Mitchell P, Dela Cruz JV, Granoff DM. Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine. J Infect Dis 2006; 193:821-8; PMID:16479517; http://dx.doi.org/10.1086/500512
   PubMed Web of Science ®Google Scholar
• Jacobson RM, Jackson LA, Reisinger K, Izu A, Odrljin T, Dull PM. Antibody persistence and response to a booster dose of a quadrivalent conjugate vaccine for meningococcal disease in adolescents. Pediatr Infect Dis J 2013; 32:e170-7; PMID:23114372; http://dx.doi.org/10.1097/INF.0b013e318279ac38
   PubMed Web of Science ®Google Scholar
• Borja-Tabora C, Montalban C, Memish ZA, Van der Wielen M, Bianco V, Boutriau D, Miller J. Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study. BMC Infect Dis 2013; 13:116; PMID:23320781; http://dx.doi.org/10.1186/1471-2334-13-116
   PubMed Web of Science ®Google Scholar
• Baxter R, Baine Y, Kolhe D, Baccarini C, Miller J, Van der Wielen M. Five-year antibody persistence and booster response to a single dose of meningococcal A, C, W and Y tetanus toxoid conjugate vaccine in adolescents and young adults: an open, randomized trial. Pediatr Infect Dis J 2015; 34:1236-43; PMID:26237742; http://dx.doi.org/10.1097/INF.0000000000000866
   PubMed Web of Science ®Google Scholar
• Bermal N, Huang LM, Dubey AP, Jain H, Bavdekar A, Lin TY, Bianco V, Baine Y, Miller JM. Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults. Hum Vaccin 2011; 7:239-47; PMID:21343698; http://dx.doi.org/10.4161/hv.7.2.14068
   PubMed Web of Science ®Google Scholar
• Quiambao BP, Jain H, Bavdekar A, Dubey AP, Kolhe D, Bianco V, Van der Wielen M, Miller JM. Persistence of the immune response two years after vaccination with quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in Asian adolescents. Hum Vaccin Immunother 2016; 12:2162-8; PMID:27152501; http://dx.doi.org/10.1080/21645515.2016.1163455
   PubMed Web of Science ®Google Scholar
• Knuf M, Baine Y, Bianco V, Boutriau D, Miller JM. Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children. Hum Vaccin Immunother 2012; 8:866-72; PMID:22485049; http://dx.doi.org/10.4161/hv.20229
   PubMed Web of Science ®Google Scholar
• Vesikari T, Forstén A, Van der Wielen M, Bianco V, Miller J. Persistent antibody responses up to 5 years following vaccination with MenACWY-TT in toddlers and children aged 1-10 years. Oral presentation at: 20 years EMGM (The European Meningococcal Disease Society); 2013 Sep 17–19; Bad Loipersdorf, Austria. Available at: http://emgm.eu/meetings/emgm2013/Abstract_Book_EMGM_2013.pdf
   Google Scholar
• Sinclair D, Preziosi MP, Jacob John T, Greenwood B. The epidemiology of meningococcal disease in India. Trop Med Int Health 2010; 15:1421-35; http://dx.doi.org/10.1111/j.1365-3156.2010.02660.x
   PubMed Web of Science ®Google Scholar
• Vyse A, Wolter JM, Chen J, Ng T, Soriano-Gabarro M. Meningococcal disease in Asia: an under-recognized public health burden. Epidemiol Infect 2011; 139:967-85; PMID:21492496
   PubMed Web of Science ®Google Scholar
• Ostergaard L, Van der Wielen M, Bianco V, Miller JM. Persistence of antibodies for 42 months following vaccination of adolescents with a meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT). Int J Infect Dis 2013; 17:e173-6; PMID:23246368; http://dx.doi.org/10.1016/j.ijid.2012.10.001
   PubMed Web of Science ®Google Scholar
• Harrison L, Kreiner C, Shutt K, Messonnier N, O'Leary M, Stefonek K, Lin H, Lynfield R, Barrett NL, Arnold KE, et al. Risk factors for meningococcal disease in students in grades 9–12. Pediatr Infect Dis J 2008; 27:193-9; PMID:18277925; http://dx.doi.org/10.1097/INF.0b013e31815c1b3a
   PubMed Web of Science ®Google Scholar
• MacLennan J, Kafatos G, Neal K, Andrews N, Cameron JC, Roberts R, Evans MR, Cann K, Baxter DN, Maiden MCJ, et al. Social behavior and meningococcal carriage in British teenagers. Emerg Infect Dis 2006; 12:950-7; http://dx.doi.org/10.3201/eid1206.051297
   PubMed Web of Science ®Google Scholar
• Andersen J, Berthelsen L, Jensen BB, Lind I. Surveillance of cases of meningococcal disease associated with military recruits studied for meningococcal carriage. Scand J Infect Dis 2000; 32:527-31; PMID:11055659; http://dx.doi.org/10.1080/003655400458820
   PubMed Web of Science ®Google Scholar
• Edwards EA, Devine LF, Sengbusch CH, Ward HW. Immunological investigations of meningococcal disease: III. Brevity of group C acquisition prior to disease occurrence. Scand J Infect Dis 1977; 9:105-10; PMID:408918; http://dx.doi.org/10.3109/inf.1977.9.issue-2.09
   PubMed Web of Science ®Google Scholar
• Neal KR, Nguyen-van-Tam JS, Slack RCB, Kaczmarski EB, White A, Ala'Aldeen DAA. Seven-week interval between acquisition of a meningococcus and the onset of invasive disease. A case report. Epidemiol Infect 1999; 123:507-9; PMID:10694164; http://dx.doi.org/10.1017/S0950268899003192
   PubMed Web of Science ®Google Scholar
• Snape MD, Kelly DF, Salt P, Green S, Snowden C, Diggle L, Borkowski A, Yu L-m, Moxon ER, Pollard AJ. Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization. Clin Infect Dis 2006; 43:1387-94; PMID:17083009; http://dx.doi.org/10.1086/508776
   PubMed Web of Science ®Google Scholar
• Wing JB, Smart L, Borrow R, Findlow J, Findlow H, Heath AW, Read RC. Kinetics of immune responses to nasal challenge with meningococcal polysaccharide one year after serogroup-C glycoconjugate vaccination. Clin Infect Dis 2011; 52:1317-23; PMID:21596673; http://dx.doi.org/10.1093/cid/cir198
   PubMed Web of Science ®Google Scholar
• Auckland C, Gray S, Borrow R, Andrews N, Goldblatt D, Ramsay M, Miller E. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J Infect Dis 2006; 194:1745-52; PMID:17109348; http://dx.doi.org/10.1086/509619
   PubMed Web of Science ®Google Scholar
• Baxter R, Baine Y, Ensor K, Bianco V, Friedland LR, Miller JM. Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age. Pediatr Infect Dis J 2011; 30:e41-e8; PMID:21200360; http://dx.doi.org/10.1097/INF.0b013e3182054ab9
   PubMed Web of Science ®Google Scholar
• Borrow R, Andrews N, Goldblatt D, Miller E. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect Immun 2001; 69:1568-73; PMID:11179328; http://dx.doi.org/10.1128/IAI.69.3.1568-1573.2001
   PubMed Web of Science ®Google Scholar
• McIntosh ED, Broker M, Wassil J, Welsch JA, Borrow R. Serum bactericidal antibody assays - The role of complement in infection and immunity. Vaccine 2015; 33:4414-21; PMID:26187262; http://dx.doi.org/10.1016/j.vaccine.2015.07.019
   PubMed Web of Science ®Google Scholar
• Maslanka SE, Gheesling LL, Libutti DE, Donaldson KBJ, Harakeh HS, Dykes JK, Arhin FF, Devi SJN, Frasch CE, Huang JC, et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. Clin Diagn Lab Immunol 1997; 4:156-67; PMID:9067649
   PubMedGoogle Scholar
• Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection–serum bactericidal antibody activity. Vaccine 2005; 23:2222-7; PMID:15755600; http://dx.doi.org/10.1016/j.vaccine.2005.01.051
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Inadvertent misadministration of meningococcal conjugate vaccine-United States, June-August 2005. MMWR Morb Mortal Wkly Rep 2006; 55:1016-7; PMID:16988640
   PubMedGoogle Scholar